Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death

• Published in: International journal of molecular sciences Vol. 23; no. 15; p. 8263
• Main Authors: Petronek, Michael S, Allen, Bryan G, Luthe, Gregor, Stolwijk, Jeffrey M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.07.2022; MDPI
• Subjects: Anions; Antiinfectives and antibacterials; Antitumor activity; Apoptosis; Aqueous solutions; Brain cancer; Cancer; Cell culture; Cell Death; Cell division; Cytotoxicity; Glioblastoma; Glioblastoma - drug therapy; Glioblastoma cells; Humans; Lipid peroxidation; Lipids; Metals; Molybdenum; Molybdenum - pharmacology; Morphology; Nanoparticles; Oxidation; Oxygen atoms; Phospholipids; Polyelectrolytes; polyoxometalate; Polyoxometallates; Transition Elements; Transition metals; Tungsten; Tungsten Compounds - pharmacology; glioblastoma; nanoparticles; cell culture; polyoxometalate
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23158263

Polyoxometalate nanoparticles (POMs) are a class of compounds made up of multiple transition metals linked together using oxygen atoms. POMs commonly include group 6 transition metals, with two of the most common forms using molybdenum and tungsten. POMs are suggested to exhibit antimicrobial effects. In this study, we developed two POM preparations to study anti-cancer activity. We found that Mo-POM (NH )Mo O ) and W-POM (H PW O ) have anti-cancer effects on glioblastoma cells. Both POMs induced morphological changes marked by membrane swelling and the presence of multinucleated cells that may indicate apoptosis induction along with impaired cell division. We also observed significant increases in lipid oxidation events, suggesting that POMs are redox-active and can catalyze detrimental oxidation events in glioblastoma cells. Here, we present preliminary indications that molybdenum polyoxometalate nanoparticles may act like ferrous iron to catalyze the oxidation of phospholipids. These preliminary results suggest that Mo-POMs (NH )Mo O ) and W-POMs (H PW O ) may warrant further investigation into their utility as adjunct cancer therapies.